Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BAY59-8862 (Cytotoxic Taxane)
BAY59-8862 · 3 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BAY59-8862 (Cytotoxic Taxane) | DRUG | 1 h intravenous infusion every 3 weeks |
| Bay 59-8862 | DRUG | 75 mg/m2 of BAY 59-8862 intravenously over one hour. Treatment will be repeated once every 3 weeks and tumor measurements will be made every 2 cycles till progression, unacceptable toxicity or consent withdrawal |
Inclusion Criteria: * Female patients with a proven diagnosis of metastatic breast cancer * Measurable disease as defined by the presence of at least one measurable lesion * Patients must have received at least 3 weeks of continuous therapy with Taxane * patient must subsequently develop progressiv...
BAY59-8862 is an investigational small molecule oncology drug developed by Bayer AG. It is also known as a cytotoxic taxane and has been studied under the names Bay 59-8862 and BAY 59-8862. It was evaluated in Phase 2 clinical trials for several advanced solid tumors, including breast cancer, non-small cell lung cancer, and renal cell carcinoma.
BAY59-8862 was studied for the treatment of advanced solid tumors, specifically metastatic breast cancer, taxane-resistant non-small cell lung cancer, and advanced renal cell carcinoma. It is an investigational agent and is not approved for any indication. All clinical trials of BAY59-8862 have been completed.
BAY59-8862 is developed by Bayer AG, which trades on the OTC market under the ticker BAYRY. Bayer sponsored the Phase 2 clinical trials evaluating the drug in breast cancer, non-small cell lung cancer, and renal cell carcinoma.
BAY59-8862 is in Phase 2 development. It has completed Phase 2 trials in metastatic breast cancer, taxane-resistant non-small cell lung cancer, and advanced renal cell carcinoma. No active trials are currently recruiting, and the drug is investigational and not approved for any indication.
BAY59-8862 has been evaluated in three completed Phase 2 trials: NCT00044564 in advanced renal cell carcinoma, NCT00044538 in taxane-resistant non-small cell lung cancer, and NCT00044525 in taxane-resistant metastatic breast cancer. These studies enrolled patients across North America, Europe, and Israel.
Yes, BAY59-8862 is the same as Bay 59-8862 and BAY 59-8862. These are alternative names for the same investigational cytotoxic taxane developed by Bayer AG. The different spellings and capitalizations refer to the identical drug candidate studied in Phase 2 oncology trials.